S&P 500   3,256.37 (-1.19%)
DOW   28,657.99 (-1.14%)
QQQ   219.00 (-1.66%)
AAPL   311.23 (-2.22%)
FB   215.37 (-1.18%)
MSFT   163.06 (-1.20%)
GOOGL   1,432.56 (-2.29%)
AMZN   1,834.42 (-1.46%)
CGC   22.09 (-2.47%)
BABA   207.72 (-2.82%)
GE   11.53 (-1.54%)
TSLA   558.58 (-1.10%)
AMD   49.54 (-1.61%)
F   8.93 (-0.78%)
BAC   33.07 (-1.43%)
DIS   136.90 (-2.27%)
S&P 500   3,256.37 (-1.19%)
DOW   28,657.99 (-1.14%)
QQQ   219.00 (-1.66%)
AAPL   311.23 (-2.22%)
FB   215.37 (-1.18%)
MSFT   163.06 (-1.20%)
GOOGL   1,432.56 (-2.29%)
AMZN   1,834.42 (-1.46%)
CGC   22.09 (-2.47%)
BABA   207.72 (-2.82%)
GE   11.53 (-1.54%)
TSLA   558.58 (-1.10%)
AMD   49.54 (-1.61%)
F   8.93 (-0.78%)
BAC   33.07 (-1.43%)
DIS   136.90 (-2.27%)
S&P 500   3,256.37 (-1.19%)
DOW   28,657.99 (-1.14%)
QQQ   219.00 (-1.66%)
AAPL   311.23 (-2.22%)
FB   215.37 (-1.18%)
MSFT   163.06 (-1.20%)
GOOGL   1,432.56 (-2.29%)
AMZN   1,834.42 (-1.46%)
CGC   22.09 (-2.47%)
BABA   207.72 (-2.82%)
GE   11.53 (-1.54%)
TSLA   558.58 (-1.10%)
AMD   49.54 (-1.61%)
F   8.93 (-0.78%)
BAC   33.07 (-1.43%)
DIS   136.90 (-2.27%)
S&P 500   3,256.37 (-1.19%)
DOW   28,657.99 (-1.14%)
QQQ   219.00 (-1.66%)
AAPL   311.23 (-2.22%)
FB   215.37 (-1.18%)
MSFT   163.06 (-1.20%)
GOOGL   1,432.56 (-2.29%)
AMZN   1,834.42 (-1.46%)
CGC   22.09 (-2.47%)
BABA   207.72 (-2.82%)
GE   11.53 (-1.54%)
TSLA   558.58 (-1.10%)
AMD   49.54 (-1.61%)
F   8.93 (-0.78%)
BAC   33.07 (-1.43%)
DIS   136.90 (-2.27%)
Log in

NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

$14.11
-0.18 (-1.26 %)
(As of 01/27/2020 01:08 PM ET)
Today's Range
$13.97
Now: $14.11
$14.22
50-Day Range
$14.29
MA: $16.29
$17.47
52-Week Range
$11.83
Now: $14.11
$29.95
Volume226,793 shs
Average Volume465,219 shs
Market Capitalization$752.63 million
P/E Ratio6.33
Dividend YieldN/A
Beta0.36
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$193.12 million
Cash Flow$0.53 per share
Book Value$5.25 per share

Profitability

Net Income$25.20 million

Miscellaneous

Employees270
Market Cap$752.63 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.


Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $1.77. The biopharmaceutical company had revenue of $59.49 million for the quarter, compared to the consensus estimate of $58.33 million. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The business's revenue for the quarter was up 21.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

4 brokerages have issued twelve-month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 41.7% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (1/18/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view." (7/31/2019)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

News coverage about VNDA stock has been trending somewhat negative on Monday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Vanda Pharmaceuticals.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totalling 4,010,000 shares, a drop of 10.3% from the December 31st total of 4,470,000 shares. Based on an average daily volume of 556,300 shares, the days-to-cover ratio is presently 7.2 days. Approximately 7.8% of the company's stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR) and Inovio Pharmaceuticals (INO).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.09%), New York State Teachers Retirement System (0.07%), Arizona State Retirement System (0.07%), Louisiana State Employees Retirement System (0.03%) and Campbell & CO Investment Adviser LLC (0.03%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Strs Ohio and Louisiana State Employees Retirement System. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC and New York State Teachers Retirement System. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $14.11.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $752.63 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  478 (Vote Outperform)
Underperform Votes:  372 (Vote Underperform)
Total Votes:  850
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel